Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard‐of‐Care and Emerging Therapeutic Strategies
Journal of Gastroenterology and Hepatology · 2026-05 · 41 (5) · 1436-1445
DOI: 10.1111/jgh.70354 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, online erschienen am 26.03.2026. Verfasst von Landon L Chan und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Translational Oncology, Hong Kong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy, Standard of Care. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for up to 80% of all cases. Most patients present at an advanced stage and are unsuitable for curative treatments. In the past 5 years, immunotherapy combination has superseded tyrosine kinase inhibitors (TKI) as the standard first‐line therapy for advanced HCC. These therapies include the combination of anti‐PD‐(L)1 with an anti‐CTLA‐4 or partner with anti‐VEGF; these agents offer unprecedented high rates of response and survival. Unfortunately, only about 20%–30% of patients respond to first‐line immunotherapy combination, and about 50% of them would develop disease progression at 6 months. In patients with progression on immunotherapy, recent prospective studies support the efficacy and safety of multiple TKIs. To further improve the efficacy of systemic therapies, novel therapeutic strategies are actively being investigated, such as with the addition of a third immune checkpoint inhibitor. Furthermore, there is increasing interest to incorporate locoregional therapies in patients with advanced disease. Three Phase 3 randomized studies (EMERALD‐1, LEAP‐012, and TALENTACE) have recently demonstrated survival benefits with the combination of trans‐arterial chemoembolization (TACE) and immunotherapy, over TACE alone. The higher response rates brought by combining locoregional therapies and systemic therapies have enabled the possibility of downstaging and conversion. In addition, cellular therapy has shown promise in early phase studies, demonstrating potential to expand the use of immunotherapy in HCC beyond immune checkpoint inhibitors. In this review, we provide an overview of the current treatment landscape and emerging therapeutic strategies for advanced HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Translational Oncology, Hong Kong, China.
- Department of Clinical Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.
ORCID-Profile: Landon L Chan, Stephen L Chan
Zitieren
APA
Chan, L. L., Chan, K. O. K., & Chan, S. L. (2026). Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard‐of‐Care and Emerging Therapeutic Strategies. Journal of Gastroenterology and Hepatology, 41(5), 1436-1445. https://doi.org/10.1111/jgh.70354
Vancouver
Chan LL, Chan KOK, Chan SL. Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard‐of‐Care and Emerging Therapeutic Strategies. Journal of Gastroenterology and Hepatology. 2026;41(5):1436-1445. doi:10.1111/jgh.70354
BibTeX
@article{Chan2026,
author = {Chan, Landon L and Chan, Kallista O K and Chan, Stephen L},
title = {Systemic Therapy for Advanced Hepatocellular Carcinoma in 2026: Current Standard‐of‐Care and Emerging Therapeutic Strategies},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
volume = {41},
number = {5},
pages = {1436--1445},
doi = {10.1111/jgh.70354}
}
EUVIMED